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ABSTRACT
In this study, we found that RAB39A, a member of the RAS oncogene family, 
was selectively expressed in cancer cells of different histotypes, by analyzing gene 
expression in human osteosarcoma cells and the cancer stem cells (CSCs) and by 
comparing them with normal cells through global transcriptomics and principal 
component analyses. We further validated RAB39A as a therapeutic target, by silencing 
its expression. The silencing impaired cancer stemness and spherogenic ability in 
vitro, as well as tumorigenesis in vivo. RNA-seq analyses in the silenced spheres 
suggested that RAB39A is associated downstream with RXRB and KLF4. Notably, 
RXRB expression was inhibited in RAB39A-silenced CSCs. Induced overexpression 
of RXRB in RAB39A-silenced cells restored spherogenic ability and tumorigenesis, 
confirming RXRB as a major effector of RAB39A. Quantitative RT-PCR analysis of 
~400 human cancer tissues showed that RAB39A was highly expressed in sarcomas 
and in malignancies of lymphoid, adrenal and testicular tissues. Our data provide the 
rationale for targeting of the RAB39A-RXRB axis as a therapy for aggressive cancers.
INTRODUCTION
Cancers develop in a variety of microenvironmental 
conditions and under the selective pressure of hostile 
conditions, such as low extracellular pH, low oxygen 
levels, and low metabolite concentrations [1]. Such hostile 
microenvironments influence tumor growth, progression, 
invasiveness, immune escape, and drug resistance [2, 3]. 
Studies aimed at identifying anticancer molecules need 
to take into account the tumor microenvironment and its 
features. An important aspect of the tumor microenvironment 
is cancer-associated extracellular acidosis, which is a general 
phenomenon mainly derived from the metabolic switch to 
persistent aerobic glycolysis, even under adequate oxygen 
conditions, the so called “Warburg effect” [4]. Acidosis 
plays a critical role in the progression of many cancers as 
it fosters chemo- and radioresistance, neo-angiogenesis, 
invasion and stemness [5]. On this basis, we used various 
“-omics” approaches to identify specific and reliable 
anticancer therapeutic targets [3, 6, 7] by comparing gene 
expression patterns in cancer cells and normal cells. The 
normal cells used here as a reference were fibroblasts (Fb) 
and mesenchymal stem cells (MSCs), cultured under both 
acidic and neutral environments. The information gathered 
in this comparative study should provide the basis for the 
development of novel and selective anticancer therapeutics. 
The present study shows that RAB39A (RAB39A, 
Member of the RAS oncogene family) is a novel 
therapeutic target and that RXRB (Retinoid X Receptor 
Beta) is one of its major effectors. RAB39A is associated 
with the acidification of phagosomes during the maturation 
phase into lysosomes [8, 9]. RXRB is a member of 
the retinoid X receptor (RXR) families mediating the 
effects of retinoic acid [10], and the mutual heterodimers 
with vitamin D receptor (VDR) are involved in cancer 
developments [11]. Even though RAB39A-RXRB axis 
has never been described as a therapeutic option for 
cancers, here, it is proved that targeting RAB39A-RXRB 
axis significantly impairs cancer stem cell (CSC) growth 
and survival. Thus, targeting RAB39A-RXRB axis is a 
promising therapeutic approach to specifically affect the 
CSC fraction of the total cancer cell population that is also 
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the tumor cell fraction associated with chemoresistance, 
recurrence, and metastasis. 
RESULTS
RAB39A is a novel target for molecular 
anticancer therapeutic strategies
As a first step, we compared global transcription 
differences of cancer cells and CSCs with normal cells 
cultured under acidic pH conditions versus neutral 
conditions. CSCs were enriched by sphere-forming 
culture, the most widely accepted method for isolating 
CSCs [12]. Under acidosis, we found that both cancer cells 
and CSCs showed up-regulation of pathways involved in 
DNA replication and cell proliferation (Supplementary 
Table 1). In contrast, Fb and MSCs that were maintained 
at low pH switched to inflammatory pathways 
(Supplementary Table 2). According to our previous data, 
this switch in Fb and MSCs may enhance invasiveness 
and metastatic potential of cancer cells, including CSCs 
[7, 13]. 
To identify novel molecular targets for the development 
of anticancer therapies, we performed a principal component 
analysis (PCA) on the global transcriptome data. Cancer 
cells, including CSCs differed from normal cells in the 
component 1 axis of PCA (Figure 1A). Among the top 100 
gene elements on this axis (Supplementary Table 3), we 
selected 10 candidates, including RAB39A, CPVL, NUP210 
and LHX2, which were robustly expressed in cancer cells 
and CSCs but not in normal MSCs or Fb in both acidic and 
neutral environments (Figure 1B). 
ShRNA-based stable knockdown of RAB39A, CPVL, 
NUP210 and LHX2 significantly impaired cancer cell 
growth under neutral and acidic conditions in HOS human 
osteosarcoma cells (Figure 1C and 1D), but had no effect on 
the growth of normal cells (Supplementary Figure 1A). As 
a result of this experiment, we considered these 4 candidate 
genes as promising therapeutic targets for cancer. We also 
identified four other genes from the component 1 axis as 
second-choice targets (Supplementary Figure 1B), namely, 
KCNG3, SLITRK5, FXYD6 and PRAME. Silencing of 
these latter genes inhibited cell growth in neutral conditions 
but not in acidic conditions (Supplementary Figure 1C). 
Similar effect was confirmed in HeLa human endocervical 
carcinoma cells (data not shown). 
The stable knockdown of RAB39A in 143B human 
osteosarcoma cells, which originated from the same host 
of HOS cells and which are well-known to form xeno-
transplanted tumors in immunodeficient mice, resulted 
in a significantly lower rate of tumorigenicity following 
xenotransplantation into a mouse model compared to 
shControl-143B and the parental cells. Silencing of CPVL 
couldn’t significantly affect in vivo tumor growth (Figure 
1E). The differences in rates of tumor development 
might result from the transplantability of each type of 
knockdown cell, and correspond to the variable survival 
rate of each type of knockdown cell at the initial stages 
of xenotransplantation, i.e., the poor tumorigenicity 
of RAB39A-knockdown cell was possibly related to 
the reduced cancer stemness in the cell. Indeed, cancer 
stemness is a phenotype that is associated with the 
ability to reproduce a similar tumor to the original one 
in immunodeficient mouse models, even after several 
passages in the cell culture [12, 14].  
Targeting RAB39A inhibits cancer stemness and 
tumorigenesis  
According to our previous results, sarcoma CSCs 
show a higher level of lysosomal acidity [15]. RAB39A 
is associated with the acidification of phagosomes during 
the maturation phase into lysosomes [8, 9], and we thus 
speculated that CSCs are a good target for anti-RAB39A 
strategies. Here, we sought to confirm the effectiveness 
of RAB39A targeting for the CSC fraction of a tumor 
cell population, by knocking-down or over-expressing 
RAB39A in parental 143B and HeLa cells via lentiviral 
transduction with specific vectors. We evaluated the 
proportion of the side population (SP) within the total 
tumor cell population. In 143B human osteosarcoma 
cells, the overexpression of RAB39A increased the SP 
fraction whereas the knockdown of RAB39A significantly 
decreased the SP fraction (Figure 2A and 2B). Induced 
overexpression or knockdown of RAB39A was confirmed 
by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) analysis (Figure 2C). RAB39A 
knockdown in 143B tumor cell population also impaired 
the expression of the stem cell marker CD44 compared 
to control (shCont) cells (Figure 2D and 2E). The results 
obtained with osteosarcoma cells were confirmed for 
HeLa cells in which we found a higher expression of 
the CXCR4 stem cell marker, a higher SP fraction in 
cells overexpressing RAB39A, and a reduced CXCR4 
expression and SP fraction in cells with knockdown of 
RAB39A (Supplementary Figure 2A to 2F). As an index of 
stemness, we also evaluated sphere-forming ability. This 
assay is the most widely accepted method for isolating 
CSCs [12] and is based on their capacity to grow as 
floating spheres in the absence of fetal serum. Sphere 
formation was significantly reduced after treatment with 
2 types of RAB39A knockdown, and silencing with either 
shRAB (4) or (5) (Figure 2F, Supplementary Figure 2G) 
significantly affected the number and the size of the 
obtained spheres (Figure 2G, Supplementary Figure 2H).
In order to evaluate the impact of RAB39A on 
tumorigenesis, RAB39A-knockdown (shRAB) cells and 
control 143B (shCont) cells were injected subcutaneously 
at serially different cell dilutions into the left and 
right sides, respectively, of the backs of mice. After 
xenotransplantation, tumor volumes and tumorigenic 
rates were measured at 3 and 5 weeks. We observed a 
significantly lower rate of tumorigenicity in the left sides 
of mice with transplantation of RAB39A-knockdown 
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Figure 1: Transcriptional comparison, mathematical ranking and shRNA-based approaches for selection of candidate 
genes with the best ranking for cancer targeting. (A) Sarcoma cells were distinguished from normal cells by component 1 axis 
of a principal component analysis, followed by global transcriptome comparison. White and black indicate transcriptional status under 
neutral (pH 7.4) and acidic (pH 6.5) conditions, respectively. Round and square symbols indicate sarcoma and normal cells, respectively; 
(B) RAB39A (bold black line) shows higher expression values in malignant cells. Each line indicates the expression value of a gene. Genes 
expressed at low levels in normal cells but abundantly expressed in malignant cells were identified as targeting candidates, and used for 
shRNA-based screening; (C) RAB39A, CPVL, NUP210 and LHX2 are primary candidates for targeting cancer cells and CSCs; (D) Cell 
growth inhibition in neutral (pH 7.4) and acidic (pH 6.8) conditions in cells transfected with shRNAs against the selected genes. Black and 
2 gray lines indicate growth of shControl and 2 kinds of gene-specific shRNA-treated HOS human osteosarcoma cells, respectively; (E) 
Upper graph, reduced tumor volumes in mice subcutaneously injected with RAB39A-knockdown 143B human osteosarcoma cells (black 
dotted line). Black, dark gray and light gray lines correspond to shControl, shCPVL and parental 143B cells, respectively. #: ANOVA on 
Day 30; F (3, 20) = 4.054, p = 0.0211 *p < 0.05, by Fisher’s PLSD, compared to shControl cells. Lower graph, silencing of RAB39A and 
CPVL expression (black and gray bars, respectively) in 143B xenotransplanted tumors with different cell lines was confirmed by qRT-PCR.
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Figure 2: Knockdown of RAB39A reduces stemness and tumorigenicity. All experiments were performed using 143B cells. 
(A) Flow cytometry of SP fraction of cells transfected with different vectors: RAB39, cells transfected with RAB39A; control cells (V5), 
cells transfected with RAB39A RNAi (shRAB(4)) or with control RNAi (shCont); (B) Graphic representation of data shown in panel A. In 
RAB39A silenced cells, SP fractions were significantly reduced; (C) RAB39A expression was confirmed by qRT-PCR. RAB39A knockdown 
used either shRAB (4) or shRAB (5); (D) Flow cytometry of CD44 expression. Left panel, RAB39 (black line) and V5 (gray line); right 
panel, shRAB (4) (black line) and shCont (gray line); (E) Graphic representation of data shown in panel D. Knockdown of RAB39A 
significantly inhibited CD44 v9 expression; (F) Reduced rate of sphere formation after knockdown of RAB39A. Scale bar, 75 µm; (G) 
After knockdown of RAB39A, sphere size (diameter) and number were significantly reduced. **p < 0.05, by Fisher’s PLSD, vs. shCont and 
parental 143B cells; (H) Six mice were xenotransplanted by subcutaneous injection with serial dilutions (106–104) of tumor cells transfected 
with different vectors. With 105-dilution, tumor volumes were significantly smaller than RAB39A knockdown tumors (shRAB) at 3 (p = 
0.0048) and 5 weeks (p = 0.0156, Mann-Whitney U-test vs. shCont). Rates (%) of tumorigenesis with respect to control tumors (shCont) 
are shown. shRAB and shCont correspond to shRAB (4) and shCont in the in vitro experiments.
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cells at a 105 cell dilution at both time points (Figure 2H, 
Supplementary Figure 3A).
RXRB is the downstream effector for RAB39A-
mediated induction of cancer stemness  
In order to identify the downstream pathways 
of RAB39A, which ultimately affect cancer stemness, 
we used RNA-seq to screen the RNA profile of spheres 
formed by 143B and HeLa cells with knockdown of 
RAB39A. We compared transcription patterns in spheres 
obtained by silencing RAB39A (shRAB (4) and (5)) 
with spheres from parental cells, spheres from RAB39A-
overexpressing cells (RAB39), and with control cells 
(shCont and V5, which are shRABs and RAB39 controls, 
respectively). We used stringent criteria to select candidate 
genes that showed at least 2-fold greater expression 
and were statistically replicated in spheres of RAB39A 
knockdown cells; the fold differences and statistical 
significance were confirmed in both 143B and HeLa 
cells (Table 1). The identified genes were processed 
using the “Pathway Analysis” software package (Strand 
NGS software version 2.0), and we focused on down-
regulated and up-regulated pathways (Table 2). “Notch 
Signaling”, “Transcriptional activity of SMAD2-3-4 
heterotrimer” and “Aryl Hydrocarbon Receptor” were 
identified as down-regulated pathways that are involved 
in NCOR2 inhibition. “Vitamin D Metabolism”, “Nuclear 
Receptors”, “Signaling by Retinoic Acid” and “Vitamin 
A and Carotenoid Metabolism” were identified as down-
regulated pathways that are involved in RXRB (Retinoid 
X Receptor Beta) inhibition. UGT2B15 and RIIAD1 were 
involved in the most important up-regulated pathways. 
RXRB inhibition resulting from RAB39A silencing 
was also confirmed by qRT-PCR analysis in spheres 
obtained from both 143B and HeLa cells (Figure 3A and 
3B), and in some cases was associated with the inhibition 
of NCOR2. UGT2B15 and RIIAD1 were increased, 
although not in all the RAB39A silenced spheres (Figure 
3A and 3B). The stemness-related genes KLF4, SOX2, 
NANOG and POU5F1/OCT3 were analyzed and only 
KLF4 was significantly reduced in RAB39A silenced 
spheres from both 143B and HeLa cells; this was also 
confirmed by qRT-PCR analysis (Figure 3A and 3B). 
Sphere-forming ability was affected by the silencing of 
RXRB in both 143B and HeLa cells that were treated 
with 2 different knockdowns, shRXRB (7) and (8), and 
similarly, by the silencing of RAB39A in cells treated with 
either shRAB (4) or shRAB (5) (Figure 3C and 3D). 
To confirm that RXRB is a downstream effector 
of RAB39A that fosters cancer stemness, we induced 
overexpression of RXRB in RAB39A-knockdown 143B 
cells and evaluated their sphere-formation ability and 
tumorigenesis in vivo. Overexpression of RXRB in 
RAB39A-deficient cells completely restored the sphere-
forming ability (Figure 4A–B). RXRB overexpression 
in the analyzed models was confirmed both by qRT-
PCR (Figure 4C) and western blot analysis (Figure 
4D). Additionally, overexpression of RXRB restored 
the tumorigenicity of RAB39A-knockdown cells in 
xenografted mice (Figure 4E, Supplementary Figure 3B). 
In the V5 controls from 143B cells, RAB39A-knockdown 
(V5_shRAB) caused significant reduction in tumor 
volume and rates of tumorigenesis compared to control 
cells (V5_shCont). RXRB overexpression in the RXRB_
shRAB cells restored tumor growth potential to the 
similar or more level as the RXRB_shCont cells. Our data 
clearly demonstrated that RAB39A and its downstream 
molecular effector RXRB fostered cancer stemness and 
tumorigenesis, and that RAB39A-RXRB axis is a potential 
target for cancer therapies. 
RAB39A expression is crucial for the 
pathogenesis of different malignancies  
Hypoxia triggers cancer glycolysis and lysosomal 
acidification and is often associated with enhanced cancer 
stemness as it is a determinant of CSC evolution in vivo 
and in CSC niches [16]. As RAB39A is involved in 
lysosome maturation [8, 9] and, according to our presented 
data, also in cancer stemness, we investigated whether 
hypoxia might modulate the expressions of RAB39A 
and RXRB, and mediate CSC survival under hypoxic 
conditions. We found that under hypoxia, RAB39A 
expression significantly increased in various cancer cell 
types, including sarcoma cells. RXRB was also induced by 
hypoxia in 5 out of 6 cancer cells, especially in HeLa and 
143B cells, even though it was reduced in MSC (Figure 
5A). Furthermore, the silencing of RAB39A significantly 
altered the viability of CSCs that were cultured under low 
oxygen tension conditions (Figure 5B), indicating that 
therapeutic targeting of RAB39A might selectively impair 
CSCs in hypoxic areas of tumors. 
To further validate RAB39A and RXRB as potential 
targets for cancer therapy, we analyzed their expression 
levels in various malignancies from clinical samples. To 
date, a high level of cytoplasmic expression of RXRB has 
been demonstrated in thyroid carcinoma [17]; however, 
the expression of RAB39A has not been explored. Here, 
we found that RAB39A was expressed in malignancies 
originating from adrenal, lymphoid, pancreas and 
testicular tissues, with a higher level of expression 
(often 100-fold higher) in clinical sarcoma samples than 
other types of cancers. RXRB was expressed in different 
cancers, irrespective of the tumor histotype (Figure 
5C). Our data conformed to The Cancer Genome Atlas 
(TCGA) database, indicating that RAB39A was highly 
expressed in testicular germ cell tumor, glioblastoma, 
glioma, pheochromocytoma, lymphoma, leukemia, 
invasive breast cancers and sarcomas, etc; and that RXRB 
was expressed more abundantly in all cancer histotypes 
(http://www.cbioportal.org/cross_cancer.do?session_
id=59d5a712498e5df2e296350a; Supplementary Figure 
4A and 4B). Interestingly, RXRB expression levels were 
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Figure 3: RXRB expression is strongly inhibited in RAB39A-silenced and slowly growing spheres, and its knockdown 
further impairs sphere formation. (A) Slowly growing spheres that were formed by 143B cells silenced for RAB39A expression 
with shRAB (4) and (5) (verified by qR-PCR). The upper panel shows RXRB and NCOR2 inhibition of expression (black and gray bars 
respectively). ANOVA: F (5, 15) = 113.722, p < 0.0001 for RXRB; F (5, 18) = 0.761, p = 0.5893 for NCOR2. The middle panel shows 
UGT2B15 and RIIAD1 induction of expression (black and gray bars, respectively). ANOVA: F (5, 18) = 16.529, p < 0.0001 for UGT2B15; 
F (5, 12) = 16.074, p < 0.0001 for RIIAD1. On the lower panel, KLF4 is enhanced in RAB39A-induced cells and inhibited in the silenced 
cells. ANOVA: F(5,13) = 188.165, p < 0.0001 for KLF4; (B) qRT-PCR validation in HeLa cells was performed similarly to A. ANOVA: F 
(5, 16) = 36.718, p < 0.0001 for RXRB; F (5, 18) = 6.449, p < 0.0001 for NCOR2; F (5, 18) = 10.707, p < 0.0001 for UGT2B15; F (5, 12) 
= 0.828, p = 0.5535 for RIIAD1; F(5,13) = 56.852, p < 0.0001 for KLF4; (C) Silencing of RXRB with shRXRB (7) and (8) in 143B cells 
reduces sphere size (diameter) and number to a similar extent as that obtained by RAB39A silencing with shRAB (4) and (5). ANOVA: 
F (5,100) = 15.230, p < 0.0001 for size; F (5, 12) = 40.029, p < 0.0001 for number; (D) Sphere-forming assay in HeLa cells, performed 
similarly to C. ANOVA: F (5,361) = 30.138, p < 0.0001 for size; F (5, 33) = 13.620, p < 0.0001 for number. Statistical evaluations in A–D 
were performed with one-way factorial ANOVA accompanied by Fisher’s PLSD test. In Fisher’s PLSD, **p < 0.05 vs. parental and controls 
(V5 or shCont), *p < 0.05 vs. parental cells.
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Figure 4: Viral transduction of RAB39A-silenced cells with RXRB restores spherogenicity in vitro, and tumorigenicity 
in vivo. (A) Silencing of RAB39A expression using a V5 sequence-containing vector strongly affected sphere formation (shRAB (4) and 
(5) silenced variants vs. shCont) of 143B cells. This effect was lost when cells were transduced with an RXRB containing viral vector. 
Scale bar, 75 µm; (B) Sphere size (diameter) and number of spheres are shown in the panel A. ANOVA: In V5 group, F (2,120) = 7.347, p 
= 0.0010 for size; F (2,30) = 3.399, p = 0.0467 for number; *p < 0.05, Fisher’s PLSD vs. shCont. In RXRB group, sphere-forming ability 
was completely restored with RAB39A-deficient cells. F (2,165) = 0.214, p = 0.8077 for size; F (2, 30) = 1.070, p = 0.3557 for number; (C) 
qRT-PCR analysis of RAB39A and RXRB (black and gray bars, respectively) in 143B transduced cells for RAB39A inhibition and RXRB 
induction; (D) Data shown in panel C for RAB39A and RXRB were confirmed by Western blot analysis. RXRB transduced variants have a 
higher level of the RXRB protein; (E) After subcutaneous injection of mice with 105 tumor cells that were previously transduced with V5- 
or RXRB-carrying vectors, tumor volumes and tumorigenic rates were measured. In the V5-control group, tumor volumes were significantly 
smaller in RAB39A-silenced tumors (shRAB) (at 3 weeks, p = 0.0033; at 5 weeks, p = 0.0360, Mann-Whitney U-test vs. shCont). The 
induced expression of RXRB restored the tumorigenicity of RAB39A-silenced 143B, as shCont and shRAB showed similar tumor volumes 
and tumorigenic rates. shRAB and shCont correspond to shRAB (4) and shCont in the in vitro experiments.
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Figure 5: RAB39A function and expression in cancer. (A) Fold changes in expression of RAB39A (2 kinds of black bars) and 
RXRB (2 kinds of gray bars) under normoxia (lighter blacks or grays), and under 1% O2 hypoxia (darker blacks or grays), in various types 
of cancer cell. Hypoxia induces RAB39A and RXRB, which were confirmed by qRT-PCR; ∆Ct value of HeLa cells under normoxia is shown 
as 1 or 20, respectively corresponding to RAB39A or RXRB. *(RAB39A) or # (RXRB), p < 0.05, Mann-Whitney U-test vs. each normoxic 
culture; (B) Viability under normoxia and hypoxia (gray and black bars, respectively) of RAB39A-silenced spheres obtained from different 
RAB39A variants was measured as luminescence values in 143B cells. The data were analyzed using one-way factorial ANOVA coupled 
to Fisher’s PLSD test. For normoxia (gray bars), ANOVA: F (5, 30) = 4.050, p = 0.0063, *p < 0.05, significant by Fisher’s PLSD vs. 143B 
cells. For hypoxia (black bars), ANOVA: F (5, 24) = 28.864, p < 0.0001, **p < 0.05, vs. shCont and parental 143B cells; (C) qRT-PCR 
analysis of RAB39A and RXRB expression in various human malignancies. RAB39A (black bars) was mainly expressed in sarcomas and 
malignancies originating from adrenal, lymphoid, pancreas and testicular tissues, whereas RXRB (gray bars) was more widely expressed, 
irrespective of tumor histotypes. Each RAB39A or RXRB value in the control normal sample was indicated as 1 or 20, respectively, for the 
representation. Generally, ∆Ct values to ACTB were 5–8 fold higher in RXRB than that of RAB39A in TaqMan® qRT-PCR; (D) RAB39A and 
RXRB expressions in lymphoid malignancies. The fold increases of RAB39A (black bars) and RXRB (gray bars) are shown, and the positive 
correlation is significantly indicated (RXRB = 3.912 + 0.275*RAB39A, r = 0.589, n = 34, p = 0.0002; Pearson’s correlation coefficient); (E) 
Hostile microenvironments like hypoxia induce RAB39A and its downstream effector RXRB, fostering cancer stemness and tumorigenesis.
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significantly correlated with RAB39A expression levels 
only in tumor tissues (r = 0.205, n = 325, p = 0.0002) 
and not in normal tissues (r = 0.202, n = 69, p = 0.0968). 
The highest level of correlation was found in lymphoid 
malignancies (RXRB = 3.912 + 0.275*RAB39A, r = 0.589, 
n = 34, p = 0.0002; Figure 5D). Together, the clinical 
sample data strengthen our hypothesis that RXRB is a 
downstream effector of RAB39A, and that RAB39A-
targeting treatments will selectively affect cancer cells and 
be unlikely to cause undue side effects in normal tissues.
DISCUSSION
In the present study, we used global transcriptomics, 
PCA and shRNA-based function screening to investigate the 
roles of RAB39A, CPVL, NUP210, LHX2, KCNG3, SLITRK5, 
FXYD6 and PRAME expression in cancer cells, including 
CSCs, under both acidic and neutral microenvironmental 
conditions. Our results indicate that these genes are selective 
therapeutic targets in cancer cells. Some of the candidate 
genes have previously been shown to be involved in cancer 
development [18–27], confirming the reliability of the 
procedure used here to detect cancer-specific targets. Among 
the candidate genes, RAB39A appears to be very promising 
since its knockdown had a clear impact on tumorigenicity 
in vivo, especially during the early steps of tumor formation, 
when cancer stemness has a major role. Therefore, we suggest 
that RAB39A is involved in cancer stemness regulation. 
Rab proteins are the largest family among the Ras-
like small GTPase superfamily, and control vesicular 
trafficking. Indeed, RAB39A function is associated with 
late endosomes and lysosomes, and regulates endocytosis 
and acidification of maturing phagosomes [8, 28]. 
RAB39A may thus be crucial for tumorigenesis since 
these processes are also linked to autophagy, which has 
an established role in cancer [29]. In autophagy, RAB39A 
negatively regulates LPS-induced autophagosome 
formation, and secretion of pro-inflammatory compounds, 
possibly through the involvement of the PI3K pathway [8, 
9]. Our previous report showed a clear connection between 
lysosomal acidification and cancer stemness [15], and we 
thus speculated that CSCs are particularly good targets for 
anti-RAB39A therapeutic strategies. In agreement with our 
speculation, our data clearly demonstrated that targeting 
RAB39A inhibits cancer stemness and tumorigenesis. This 
is the first time that RAB39A has been studied in cancer 
biology, with the exception of a report on mouse Neuro2A 
cells and their involvement in neuronal differentiation, 
such as retinoic acid-induced neurite morphology [30]. 
In order to further explore the RAB39A downstream 
pathways that affect cancer stemness, we used RNA-seq 
to screen spheres produced by cells with a knockdown 
of RAB39A expression. In combination with a cellular 
functional analysis following RAB39A knockdown and 
RXRB augmentation, this strategy enabled us to identify 
RXRB as a downstream effector of RAB39A that fosters 
cancer stemness. RXRB is a member of the RXR family of 
nuclear receptors that mediates the effects of retinoic acid, 
and it forms heterodimers with the retinoic acid receptor 
(RAR), thyroid hormone and VDR, increasing both DNA 
binding and transcriptional function on their respective 
response elements [10]. RXRB is widely expressed 
and plays a crucial role in spermatogenesis [31–33]. 
Furthermore, the mutual heterodimers between RXR and 
VDR are involved in cancer developments, and activated 
Ras-Raf-MAPK-ERK can engage in the classical VDR 
pathway to modulate variously gene expressions [11]. 
Ras-like small GTPase activity contained in RAB39A may 
contribute to cancer developments through RXR and VDR 
signaling. RXRB is also expressed in various malignancies 
[17, 34–38] and promotes cell survival/proliferation in 
triple-negative breast cancer [39], thus indirectly confirming 
a crucial role of the RAB39A-RXRB axis in modulating 
cancer stemness. In addition, TCGA database showed that 
genetic amplification of RAB39A-RXRB was often seen in 
various types of malignancies especially like breast and 
neuroendocrine prostate cancers (Supplementary Figure 
4C), suggesting that the RAB39A-RXRB axis plays a 
prominent role for development of various malignancies.
Intratumoral hypoxia is a widely accepted characteristic 
of CSC evolution in vivo and in CSC niches [16]. We focused 
on evaluating the expression of RAB39A under hypoxic 
conditions and the effects of its inhibition. Our data showed 
that RAB39A expression increased in hypoxic cancer cells and 
that its inhibition significantly reduced the viability of hypoxic 
CSCs. Hypoxia is a trigger of cancer glycolysis; lysosomal 
compartmentalization is the most effective detoxification 
mechanism for high proton intracellular contents associated 
with glycolysis, and RAB39A activity might therefore be 
required for lysosomal acidification [8, 9, 28]. Taken together, 
our data from the preclinical model strongly suggested that 
targeting the RAB39A-RXRB axis might result in selective 
impacts on CSCs in hypoxic areas of tumors.
Through analyses of both clinical samples and 
TCGA database, we confirmed that RAB39A was expressed 
in sarcomas and malignancies of lymphoid, adrenal and 
testicular tissues; and RXRB abundance was constantly 
widespread in various cancers, suggesting that RXRB 
functions with the saturated level in cancers. Induced 
RXRB showed the restoration of both spherogenesis 
and tumorigenesis, but further increase of its expression 
couldn’t significantly enhance these abilities. On the 
contrary, silencing of RXRB or RAB39A inhibited the 
spherogenicity with a major and significant effect, possibly 
through impairment of the stemness. These data suggest that 
RXRB functioning protein is at almost saturated activity 
and that RXRB-mediated cancer stemness has been already 
maximized in various cancers. It is why inhibiting RAB39A 
or RXRB can critically affect cancer stemness. In the 
clinical sample analysis, RXRB levels were not correlated 
with RAB39A expression levels in normal tissues, but a 
significant correlation was present in tumor tissues. These 
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observations additionally support our hypothesis that RXRB 
is a downstream effector of RAB39A, and that targeting 
RAB39A will selectively affect cancer and CSCs and be 
unlikely to cause undue side effects in normal tissues.
In conclusion, this study has identified and validated 
RAB39A as a promising therapeutic target in various 
human malignancies. We demonstrated that RAB39A-
RXRB axis plays a prominent role in cancer development 
and stemness, and that targeting RAB39A and inhibiting 
its downstream molecular effecter RXRB strongly 
Table 1: Genes that were significantly changed in RAB39A-silenced and slowly growing spheres
Down_Gene Symbol Gene ID Fold Change* p-values (Corr) **
MIR3916 100500849 -4.2365184 0
JMY 133746 -2.0020356 0
AMH 268 -5.758692 0
SNORD35B 84546 -2.877896 0
TSEN54 283989 -2.6107361 0
SNORD117 692233 -2.8293664 0
FBRSL1 57666 -2.243737 0
MIR23A 407010 -2.193306 0
SNORA23 677808 -3.2678993 0
PIGW 284098 -2.149463 0
SNORA8 654320 -4.5891285 0.02020202
LOC100288162 100288162 -2.2554677 0.02020202
RFNG 5986 -2.2187188 0.02020202
SNORA9 677798 -2.9003572 0.02020202
RXRB 6257 -2.4855814 0.02020202
CHSY1 22856 -2.0405383 0.030303031
NCOR2 9612 -2.1620538 0.030303031
STX16 8675 -2.0439882 0.030303031
SNX25 83891 -2.3050969 0.030303031
ZNF524 147807 -3.4322982 0.030303031
SNORA55 677834 -2.3716238 0.04040404
SSH1 54434 -2.002753 0.04040404
Up_Gene Symbol
RIIAD1 284485 3.8731875 0
LOC101929741 101929741 7.2783465 0
LINC00240 100133205 3.3969362 0
LINC00845 100507058 5.435211 0
TRIM64B 642446 6.6734176 0
C17orf98 388381 5.1731205 0
PYY 5697 4.068584 0
NAPSA 9476 4.2063127 0
MAGEB10 139422 4.031648 0
ITIH6 347365 6.3592973 0
UGT2B15 7366 10.825695 0.02020202
LY6D 8581 2.8018305 0.02020202
LOC100507377 100507377 3.4407458 0.02020202
LOC100506700 100506700 6.667328 0.030303031
*These genes were statistically down- or up-regulated in RAB39A-silenced and slowly growing spheres.
**Replicate analysis (Strand NGS); Moderate T test followed by Westfall Young correction was performed between RAB39A-knockdowns and the other 
spheres. Genes showing significant changes in expression in RAB39A-silenced and slowly growing spheres. RNA-seq analyses of 143B and HeLa cell 
spheres were used to obtain transcription profiles of slow growing cancer spheres in which expression of RAB39A had been silenced (shRAB(4) and (5)), 
for comparison to fast growing spheres, including parental cultures, RAB39A-overexpressing cells (RAB39), and transduced controls (V5 and shCont). 
Genes that were up-regulated or down-regulated > 2-fold were selected as candidates; these were statistically confirmed in the analysis of both 143B and 
HeLa spheres. T-test followed by Westfall Young correction was performed using “Replicate analysis” (Strand NGS software version 2.0). 
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impairs tumorigenesis and cancer stemness (Figure 5E), 
with particular regard to musculoskeletal sarcomas and 
lymphoid malignancies. RAB39A and RXRB thus deserve 
further investigation that will allow the development of 
novel drugs for more effective and novel anti-cancer 
therapeutic strategies. 
MATERIALS AND METHODS
Cell lines  
Human osteosarcoma cells (MG-63, HOS) and 
normal fibroblasts (TIG-108, TIG-121) were obtained from 
the Japanese Collection of Research Bioresources (Osaka, 
Japan). Primary cultures of mesenchymal stromal cells 
(MSCs) (#305526, #351482, #326162, #367500) were 
acquired from Lonza (MD). Saos-2 human osteosarcoma 
cells were obtained from RIKEN BioResource 
Center (RIKEN BRC, Tsukuba, Japan). HeLa human 
endocervical carcinoma and 143B human osteosarcoma 
cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). Cells were cultured 
in Dulbecco’s modified Eagle’s medium containing 
10% fetal bovine serum, supplemented with penicillin 
(50 units/mL) and streptomycin (50 mg/mL) with 10 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid to achieve pH 7.4, or with 10 mM piperazine-1,4-
bis(2-ethanesulfonic acid) to achieve pH 6.5. Cells were 
incubated at 37°C in a humidified chamber supplemented 
with 5% CO2.
Sphere-forming culture  
Briefly, osteosarcoma cells with or without lentiviral 
transfection were cultured in 6-well plates (30,000 
cells/well) coated with polyhema (Sigma-Aldrich) in 
anchorage-independent conditions. DMEM-F12 complete 
medium was used at either pH 6.5 or 7.4. Progesterone 
Table 2: Pathways affected by RAB39A reduction in CSC spheres
Down_Pathway Pathway Entities #
Matched 
Entities * p-value 
**
Hs_Notch_Signaling_Pathway_WP268_70096 46 2 2.88E-04
Hs_Vitamin_D_Metabolism_WP1531_82221 11 1 0.005967482
Hs_Post-translational_modification-_synthesis_of_GPI-
anchored_proteins_WP1887_83233
26 1 0.013513307
Hs_Nuclear_Receptors_WP170_71083 38 1 0.020471161
Hs_Signaling_by_Retinoic_Acid_WP3323_83286 42 1 0.0226026
Hs_Vitamin_A_and_Carotenoid_Metabolism_WP716_
83589
43 1 0.023134766
Hs_miRNAs_involved_in_DNA_damage_response_
WP1545_84697
69 1 0.024729608
Hs_Transcriptional_activity_of_SMAD2-SMAD3-SMAD4_
heterotrimer_WP2755_83472
48 1 0.024729608
Hs_Aryl_Hydrocarbon_Receptor_WP2586_85335 48 1 0.025260668
Hs_Pre-NOTCH_Expression_and_Processing_WP2786_83418 68 1 0.027382156
Up_Pathway
Hs_Tamoxifen_metabolism_WP691_85084 21 1 0.007245274
Hs_Glucuronidation_WP698_79224 26 1 0.00896314
Hs_Endothelin_Pathways_WP2197_74852 33 1 0.011020934
Hs_Surfactant_metabolism_WP3579_83469 36 1 0.011363514
Hs_Phase_II_conjugation_WP1880_83364 97 1 0.031381793
#The gene number on the pathway, according to the database.
*The number of genes that were statistically down- or up-regulated in poorly grown cancer-spheres.
**Pathway analysis (Strand NGS); Fisher exact test was performed between the Entity List of down-regulated genes and 
WikiPathway. Pathways affected by RAB39A reduction in CSC spheres. Using RNA-seq analysis of 143B and HeLa sphere 
cultures, we profiled transcription in RAB39A-knockdown spheres (shRAB (4) and (5)) in respect to untreated spheres, 
RAB39A-overexpressing spheres (RAB39), and controls (V5 for RAB39, and shCont for shRAB (4) and (5)). We selected 
genes with 2-fold higher or lower expression in RAB39A silenced spheres, and that were also confirmed to be statistically 
reproducible in a HeLa sphere model. Then, the pathways associated with the selected candidate genes were identified by 
using the “Pathway Analysis” software package (Strand NGS software version 2.0).  
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(20 nM), putrescine (10 mg/mL), sodium selenite (30 
nM), apo-transferrin (100 mg/mL), and insulin (25 
mg/mL) (Sigma-Aldrich) were added to the complete 
medium. Fresh human epidermal growth factor (20 ng/
mL) and basic fibroblast growth factor (10 ng/mL) (Gibco-
Life Technologies) were added twice a week. After 10 
days, bright field images were acquired using a Leica 
DMI4000B (Leica Microsystems). Only spheres with a 
diameter of more than 20 μm were counted. Analysis of 
cell diameter was performed with Leica Application Suite 
Software (Leica Microsystems). 
RNA extraction and RNA-Seq analysis  
Total RNA from cell cultures or from spheres was 
extracted using guanidinium thiocyanate-phenol-chloroform. 
The total RNA was quantified with a Bioanalyzer (Agilent, 
Santa Clara, CA) following the manufacturer‘s instructions. 
A RIN (RNA Integrity Number) of 10 and an A260/A280 
ratio over 1.8 were obtained for the total RNA.
Following the manufacturer‘s protocol, the 
library of template molecules for high throughput DNA 
sequencing was converted from the total RNA using 
TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, 
CA). For detecting RAB39A-cancer stemness pathways, 
the library was prepared from the total RNA isolated 
from spheres, using the Ribo-Zero rRNA Removal Kit 
(Illumina). The library was quantified with a Bioanalyzer 
(Agilent) following the manufacturer‘s instructions. The 
library (4 pM) was subjected to cluster amplification on 
a Single Read Flow Cell v4 with a cluster generation 
instrument (Illumina). Sequencing was performed on 
Genome Analyzer GAIIx for 76 cycles or HiSeq 2500 for 
101 cycles using Cycle Sequencing v4 reagents (Illumina). 
Image analysis and base calling were performed 
using Off-Line Basecaller Software 1.6 (Illumina). 
Human genome build 19 (hg19) was downloaded from 
the University of California, Santa Cruz genome browser 
(http://genome.ucsc.edu/) as the analytical reference. 
Reads were aligned using Strand NGS software (version 
2.0, Strand Scientific Intelligence Inc., San Francisco, CA) 
with the sequence data sets. Transcript coverage for every 
gene locus was calculated from the total number of filter 
reads that mapped to exons. These analyses and filtering 
were performed using default parameters. All the advanced 
analyses for quantification with TMM normalization 
algorithm, expression analysis, pathway analysis with 
WikiPathway data, and principal component analysis 
were also performed using Strand NGS software. Genes 
with significantly different expressions were identified 
by the fold change method (fold change > 2), statistically 
analyzed by Westfall-Young permutation procedure (p 
< 0.05), and categorized into particular pathways using 
Pathway analysis (p < 0.05). All new data has been 
deposited in DDBJ/EMBL/GenBank under DRA004087, 
DRA004091 and DRA005595.
Plasmid DNA and gene transfer  
Lentiviral shRNA vectors for RAB39A (shRAB(4) 
and (5)), RXRB (shRXRB(7) and (8)), non-silencing 
control (shCont) and the other targets (CPVL, NUP210, 
LHX2s, KCNG3, SLITRK5, FXYD6 and PRAME) 
were purchased from Dharmacon (GE Healthcare, 
UK). Lentiviral cDNA vectors for RAB39A and RXRB 
were obtained from Dharmacon and OriGene (MD), 
respectively. V5 sequence-containing pLenti6 vector 
(Invitrogen, Thermo, MA) without any specific cDNA, 
was used as the overexpression control. Lentivirus 
transferring shRNA or cDNA were prepared with 
Lenti-X™ HTX packaging system (Clontech, Takara Bio, 
Shiga, Japan) according to the manufacturer’s instructions. 
HOS, HeLa and 143B cells transferred by >20 MOI of 
each lentivirus were selected in the presence of 3 μg/ml 
puromycin or 10 μg/ml blasticidin, expanded and used in 
the experiments. 
WST-8 assay for cell viability  
HOS and HeLa cells were cultured in 96-well plates 
at a density of 1×103 per well, and cell viability assays 
were carried out by a Cell Counting Kit-8 (Dojindo 
Molecular Technologies Inc, Kumamoto, Japan). WST-
8 reagent solution was added to each well, and the 
absorbance at 450 nm (OD450) was measured by a 
microplate reader after the microplate was incubated with 
the reagent for 2 hours at 37°C, in accordance with the 
manufacturer's instructions. 
Mice and xenografting of human osteosarcoma 
cells  
Seven-week-old BALB/c nu/nu nude mice (CLEA 
Japan, Inc., Tokyo, Japan) transplanted with either 143B 
human osteosarcoma cells or genetically manipulated 
variants were used in the experiments. A minimum of 
6 mice was xenotransplanted with 143B variant cells in 
each group. A subcutaneous injection of 1 × 106 cells of 
143B or a variant was made into the right dorsal flank of 
each mouse. After the establishment of palpable tumors 
(about ≥ 5 days), mouse body weight and external tumor 
volume were determined twice a week. Tumor volume 
was calculated using the formula A2 × B/2, where A and B 
represents the smallest diameter and the largest diameter, 
respectively. The use of the animals in the experimental 
protocols was reviewed and approved by the Committee 
of Research Center for Animal Life Science in Shiga 
University of Medical Science (Approved No. 2015-3-8). 
In order to evaluate the xenotransplantability of 
RAB39A-knockdown cells, RAB39A knockdown and the 
control 143B cells (shRAB and shCont) were transplanted 
with serial cell dilutions of 106–104 tumor cells into each 
left and right backs of 6 mice each, respectively (a total of 
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18 mice was used). After xenotransplanting each dilution 
of cells, tumor volumes and tumorigenic rates were 
measured in shRAB and shCont 143B tumors at 3 and 5 
weeks. shRAB corresponds to shRAB(4) in the in vitro 
experiments.
After transduction with V5 or RXRB carrying vectors 
(labeled as V5_ or RXRB_) in 143B cells, tumorigenicity 
for RAB39A knockdown and the control cells (labeled as 
_shRAB or _shCont) were evaluated. In this case, referring 
to the previous data using serial cell dilution transplants, 
105 tumor cells of 2 pairs of the knockdown variants (V5_
shRAB & _shCont; and RXRB_shRAB &_shCont) were 
xenotransplanted into the backs of 6 mice (a total of 12 mice 
was used), and tumor volumes and tumorigenic rates were 
measured at 3 and 5 weeks. 
Quantitative reverse transcription polymerase 
chain reaction (qRT-PCR)  
Using the acid guanidinium thiocyanate-phenol-
chloroform method, total RNAs were obtained from cultured 
cells and 13 clinical sarcoma samples, which had been 
collected and banked with the written informed consent 
of patients and after approval by the Ethics Committee of 
Istituto Ortopedico Rizzoli (No. 0033626), and cDNA were 
produced by SuperScript® VILO™ Master Mix (Thermo). 
TissueScan™ Cancer and Normal Tissue cDNA Arrays 
(#CSRT103, OriGene, MD) were applied for evaluating 
~400 clinically human cancer tissues, covering different 
malignancies of adrenal grand, breast, cervix, colon, 
endometrium, esophagus, kidney, liver, lung, lymphoid tissue, 
ovary, pancreas, prostate, stomach, testis, thyroid grand, 
urinary bladder and uterus (described precisely in http://www.
origene.com/qPCR/Tissue-qPCR-Arrays.aspx). Quantitative 
PCR was performed using a TaqMan® Fast Advanced master 
mix and StepOnePlus™ Real-Time PCR system (Thermo). 
Gene expression was normalized with human beta actin 
(ACTB: #4326315E) as an endogenous control in each 
tube, and the relative levels were calculated using the ΔΔCt 
model [40]. Probe and primer sets were prepared for human 
RAB39A (Hs00380029_m1), RXRB (Hs00232774_m1), 
CPVL (Hs01073862_m1), NUP210 (Hs00227779_m1), 
LHX2 (Hs00180351_m1), NCOR2 (Hs00196955_m1), 
UGT2B15 (Hs00870076_s1), RIIAD1 (Hs01380113_g1) and 
KLF4 (Hs00358836_m1); and purchased from Thermo. Each 
assay was repeated at least three times.
Side population and stem-related surface maker 
analyses  
To detect cancer stem-like cells, we carried out 
analyses for the side population (SP) and stem-related cell 
surface markers, such as CD133, CD44 v5 and CXCR4. 
Vybrant® DyeCycle™ Violet staining (10 μM) of human 
stem cells enabled SP fractions to be measured by contrast 
with those pre-incubated with 10 μM fumitremorgin C 
that inhibits ABCG2 drug transportation. The cells were 
washed with PBS, harvested by trypsin, and reconstituted 
to a final concentration of 1 × 106 cells/ml in Live cell 
imaging® reagents (Life Technologies, Thermo), together 
with the DyeCycle™ staining reagent for 30 min, Then, 
the cells were analyzed under 405 nm excitation in an 
Attune® Acoustic Focusing Cytometer (Thermo). 
For stem-related cell surface marker analysis, the 
antibody for CD133 (AC133, Miltenyi Biotec, CA) or CD44 
v9 (RV3, Cosmo Bio, Tokyo, Japan) was detected using Alexa 
Fluor® 488 goat anti-mouse or anti-rat IgG (H+L), or CXCR4 
(CD184, Miltenyi) pre-conjugated with phycoerythrin. Anti-
human CD44 v9 (RV3) specifically detects CD44 variant 
isoforms (CD44 v8–10), which contribute to the defense 
against reactive oxygen species by promoting cystine uptake 
for reduced glutathione, and which drives tumor growth, 
chemoresistance and metastasis [41, 42]. From a preliminary 
analysis, CD44 v9 and CXCR4 were known to be abundant 
in 143B and HeLa cells, respectively, and were therefore used 
to evaluate each stem-like fraction; CD133 staining was too 
subtle to detect or to evaluate intensities in either cell type 
(Supplementary Figure 2A). Harvested cells (1 x 106) were 
stained, resuspended in 1 ml Live cell imaging® reagents 
(Thermo), and gated in a forward scatter vs. side scatter, 
excluding debris or cell aggregations. Then, the gated cell 
populations were evaluated for expression of each surface 
maker expression under 488 nm excitation using an Attune® 
Acoustic Focusing Cytometer (Thermo).
Immunoblotting  
Cells were lysed in Laemmli-SDS buffer; the 
solution was subjected to SDS-polyacrylamide gel 
electrophoresis, and then electro-transferred to membrane 
filters (Immuno-Blot PVDF membranes, Bio-Rad 
Laboratories, Richmond, CA). The filters were incubated 
overnight with a primary antibody of RAB39A (#13355-
1-AP, Proteintech, IL), RXRB (#8715, Cell Signaling 
Technology, MA) or α-tubulin (#T9026, DM1A, 
Sigma-Aldrich, MO) in TBS-T containing 2% bovine 
serum albumin and incubated for 1 hour in horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse 
secondary antibodies (Cell Signaling Technology) diluted 
1:10,000 in TBS-T containing 2% bovine serum albumin. 
Immunoreactivity was detected using the Luminata 
Classico Western HRP substrate (Millipore Corporation) 
and an LAS4000 bioimager (Fujifilm, Tokyo, Japan). 
Evaluation for sphere viability  
Induced and reduced RAB39A variants, RAB39, 
V5, parental, shCont, shRAB(4) and (5), of 143B and 
HeLa cells were seeded at 3000 cells/well into non-
adhesively coated 96 well plates (Low Cell Attachment 
Plate PrimeSurface® MS-9096V, Sumitomo Bakelite, 
Tokyo, Japan), and incubated in complete DMEM-F12 
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medium for sphere-forming culture, under normoxic 
and hypoxic (1% O2) conditions. The survival of spheres 
was analyzed on Day 3 (72 hours after seeding) using a 
CellTiter-Glo® 3D Cell Viability Assay, as a luminescence 
value (Promega, Madison, WI).
Statistical analysis  
RNA-seq data analysis was performed using 
Strand NGS software version 2.0 (Strand Scientific 
Intelligence Inc.). Other statistical analyses were 
performed with StatView™ version 5.0 software for 
Windows (SAS Institute Inc). Results are reported as 
means ± standard error. One-way factorial ANOVA 
accompanied by Fisher’s PLSD test was used to 
compare multiple group means. Non-parametric Mann-
Whitney U tests were used to compare two group 
means. Pearson’s correlation coefficient tests were used 
to identify significant correlations between RAB39A 
and RXRB expression in tumor and normal samples. 
A p-value of < 0.05 was considered statistically 
significant.
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